BioAge Labs, Inc.
BioAge Labs, Inc. (BIOA) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · BIOA · as of Jun 8, 2026
Key Statistics
Explore BioAge Labs, Inc. Data
bioa stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 3 · Buy rate: 66.7%
The BIOA analyst consensus is Buy, based on ratings from 3 Wall Street analysts over the past 3 months. The average 12-month price target is $42.20, representing +172.08% upside from the current price of $15.51.
Competitors & Peers
bioa competitorsBIOA
ACB
ALLO
AVIR
CABA
CGCStock Performance
Full HistoryAbout BioAge Labs, Inc.
BioAge Labs, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for metabolic illnesses. The company employs a distinctive technology platform…
what is bioage labs, inc. · bioa stock overview · bioage labs, inc. company profile · who is bioage labs, inc. ceo · bioa NASDAQ · bioage labs, inc. headquarters · bioage labs, inc. business segments
About Stock Overview & Key Data
BioAge Labs, Inc. (BIOA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Sep 26, 2024. As of the latest trading session, BIOA stock price is $15.51, with a market capitalization of $583.9M. The stock has returned +261.35% over the past 12 months and +17.44% year-to-date.
According to 3 Wall Street analysts, the consensus rating for BioAge Labs, Inc. stock is Buy, with an average 12-month price target of $42.20. In fiscal year 2025, BioAge Labs, Inc. reported revenue of $9.0M and net income of -$80.6M. For detailed data — including BioAge Labs, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, BioAge Labs, Inc. (BIOA) stock price is $15.51. The stock is traded on NASDAQ under the ticker symbol BIOA. The 52-week range is $4.07 – $24.00.